Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 05, 2022 at 04:14 pm EDT
Share
Natera, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 194.13 million compared to USD 152.32 million a year ago. Net loss was USD 138.6 million compared to USD 63.85 million a year ago. Basic loss per share from continuing operations was USD 1.45 compared to USD 0.74 a year ago. Diluted loss per share from continuing operations was USD 1.45 compared to USD 0.74 a year ago.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.